Sugi Predict

Sugi Predict / Compounds / SCHEMBL4261983

SCHEMBL4261983

SCHEMBL4261983

COC(=O)c1ccc2cnn(C)c2c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PDE1C Q14123 2/20 0.57
▸ VNN1 O95497 1/20 0.51
▸ PTGER3 P43115 1/20 0.49
▸ KDM4E B2RXH2 2/20 0.48
▸ ALDH1A1 P00352 1/20 0.47
▸ POLB P06746 1/20 0.47
▸ HPGD P15428 1/20 0.47
▸ APOBEC3A P31941 1/20 0.47
▸ SMN1; SMN2 Q16637 1/20 0.47
▸ HSD17B10 Q99714 1/20 0.47
▸ APOBEC3G Q9HC16 1/20 0.47
▸ CDK8 P49336 2/20 0.46
▸ CCNC P24863 1/20 0.46
▸ CA12 O43570 1/20 0.45
▸ CA1 P00915 1/20 0.45
▸ CA2 P00918 1/20 0.45
▸ CA7 P43166 1/20 0.45
▸ XDH P47989 1/20 0.45
▸ CA9 Q16790 1/20 0.45
▸ CA14 Q9ULX7 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29491497 1.00 PDE1C (0.57) PDE1CVNN1PTGER3KDM4EALDH1A1
SCHEMBL30041675 0.88 PDE1C (0.57) PDE1CVNN1PTGER3KDM4EALDH1A1
SCHEMBL1144917 0.88 PDE1C (0.57) PDE1CVNN1PTGER3KDM4EALDH1A1
SCHEMBL763629 0.85 CA12 (0.50) PDE1CVNN1PTGER3KDM4EALDH1A1
SCHEMBL29491465 0.84 PTGER3 (0.52) PDE1CPTGER3KDM4EALDH1A1POLB
SCHEMBL15656940 0.84 PTGER3 (0.52) PDE1CPTGER3KDM4EALDH1A1POLB
SCHEMBL24339233 0.83 MAOA (0.54) PDE1CPTGER3KDM4EALDH1A1POLB
SCHEMBL30174399 0.83 KMO (0.47) PDE1CPTGER3KDM4EALDH1A1POLB
SCHEMBL24338498 0.83 KMO (0.47) PDE1CPTGER3KDM4EALDH1A1POLB
SCHEMBL30174418 0.83 MAOA (0.54) PDE1CPTGER3KDM4EALDH1A1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12258318-B2 Synthesis method for 1-methyl-1H-indazole-6-carboxylic acid ACCELA CHEMBIO CO., LTD. (CN) 2025-03-25 — — US claimed
US-20220235010-A1 SYNTHESIS METHOD FOR 1-METHYL-1H-INDAZOLE-6-CARBOXYLIC ACID ACCELA CHEMBIO CO., LTD. (CN) 2022-07-28 — — US claimed
WO-2020253533-A1 SYNTHESIS METHOD FOR 1-METHYL-1H-INDAZOLE-6-CARBOXYLIC ACID 韶远科技（上海)有限公司 2020-12-24 — — WO claimed
US-20250215012-A1 IKZF2 DEGRADERS AND USES THEREOF UNIV MICHIGAN (US) 2025-07-03 — — US disclosed
CN-119731179-A IKZF2 degradation agent and application thereof 密歇根大学董事会 2025-03-28 — — CN disclosed
US-12258318-B2 Synthesis method for 1-methyl-1H-indazole-6-carboxylic acid ACCELA CHEMBIO CO., LTD. (CN) 2025-03-25 — — US disclosed
EP-4499649-A1 IKZF2 DEGRADERS AND USES THEREOF Regents of the University of Michigan (US) 2025-02-05 — — EP disclosed
CN-115515956-B Benzimidazole derivative, and preparation method and medical application thereof 深圳信立泰药业股份有限公司 2024-06-25 — — CN disclosed
WO-2023183540-A1 IKZF2 DEGRADERS AND USES THEREOF REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2023-09-28 — — WO disclosed
CN-115515956-A Benzimidazole derivative and preparation method and medical application thereof 深圳信立泰药业股份有限公司 2022-12-23 — — CN disclosed
US-20220235010-A1 SYNTHESIS METHOD FOR 1-METHYL-1H-INDAZOLE-6-CARBOXYLIC ACID ACCELA CHEMBIO CO., LTD. (CN) 2022-07-28 — — US disclosed
EP-1140203-B1 VITRONECTIN RECEPTOR ANTAGONIST PHARMACEUTICALS BRISTOL MYERS SQUIBB PHARMA CO (US) 2007-05-23 — — EP disclosed
US-20050154185-A1 Vitronectin receptor antagonist pharmaceuticals BRISTOL-MYERS SQUIBB PHARMA COMPANY 2005-07-14 — — US disclosed
US-6838074-B2 Simultaneous imaging of cardiac perfusion and a vitronectin receptor targeted imaging agent BRISTOL-MYERS SQUIBB COMPANY (US) 2005-01-04 — — US disclosed
US-20040208823-A1 SIMULTANEOUS IMAGING OF CARDIAC PERFUSION AND A VITRONECTIN RECEPTOR TARGETED IMAGING AGENT LANTHEUS MEDICAL IMAGING, INC. 2004-10-21 — — US disclosed
US-6794518-B1 Vitronectin receptor antagonist pharmaceuticals BRISTOL-MYERS SQUIBB PHARMA COMPANY 2004-09-21 — — US disclosed
EP-1296678-A2 VITRONECTIN RECEPTOR ANTAGONIST PHARMACEUTICALS FOR USE IN COMBINATION THERAPY Bristol-Myers Squibb Pharma Company (US) 2003-04-02 — — EP disclosed
WO-2001098294-A2 VITRONECTIN RECEPTOR ANTAGONIST PHARMACEUTICALS FOR USE IN COMBINATION THERAPY BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) 2001-12-27 — — WO disclosed
EP-1140203-A2 VITRONECTIN RECEPTOR ANTAGONIST PHARMACEUTICALS Du Pont Pharmaceuticals Company (US) 2001-10-10 — — EP disclosed
WO-2000035488-A2 VITRONECTIN RECEPTOR ANTAGONIST PHARMACEUTICALS DU PONT PHARMACEUTICALS COMPANY (US) 2000-06-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250215012-A1 IKZF2 DEGRADERS AND USES THEREOF IKZF1, IKZF2, IKZF3 PDE1C 4131/4885VNN1 3263/4885PTGER3 3972/4885
US-20040208823-A1 SIMULTANEOUS IMAGING OF CARDIAC PERFUSION AND A VITRONECTIN RECEPTOR TARGETED IMAGING AGENT TNNI3, ASGR1, TNNT2 PDE1C 699/4885VNN1 725/4885PTGER3 3276/4885
US-20050154185-A1 Vitronectin receptor antagonist pharmaceuticals ADGRF1, RXFP1, VCAM1 PDE1C 1689/4885VNN1 2455/4885PTGER3 1844/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.